CA2898732A1 - Inhibiteurs d'un recepteur des ƒstrogenes - Google Patents

Inhibiteurs d'un recepteur des ƒstrogenes Download PDF

Info

Publication number
CA2898732A1
CA2898732A1 CA2898732A CA2898732A CA2898732A1 CA 2898732 A1 CA2898732 A1 CA 2898732A1 CA 2898732 A CA2898732 A CA 2898732A CA 2898732 A CA2898732 A CA 2898732A CA 2898732 A1 CA2898732 A1 CA 2898732A1
Authority
CA
Canada
Prior art keywords
era
cells
bhp
upr
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2898732A
Other languages
English (en)
Inventor
Mao CHENGJIAN
David J. Shapiro
Neal D. Andruska
Mathew M. Cherian
Lily MAHAPATRA
William HELFERICH
Xujuan YANG
Xiaobin ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2898732A1 publication Critical patent/CA2898732A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2898732A 2013-01-18 2014-01-21 Inhibiteurs d'un recepteur des ƒstrogenes Abandoned CA2898732A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754292P 2013-01-18 2013-01-18
US61/754,292 2013-01-18
PCT/US2014/012405 WO2014113820A1 (fr) 2013-01-18 2014-01-21 Inhibiteurs d'un récepteur des œstrogènes

Publications (1)

Publication Number Publication Date
CA2898732A1 true CA2898732A1 (fr) 2014-07-24

Family

ID=51210145

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2898732A Abandoned CA2898732A1 (fr) 2013-01-18 2014-01-21 Inhibiteurs d'un recepteur des ƒstrogenes

Country Status (5)

Country Link
EP (1) EP2945646A4 (fr)
AU (1) AU2014207272A1 (fr)
CA (1) CA2898732A1 (fr)
IL (1) IL240019A0 (fr)
WO (1) WO2014113820A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107164519A (zh) * 2017-06-26 2017-09-15 深圳优圣康医学检验所有限公司 一种基于荧光pcr检测esr1基因突变的引物及探针
MX2021000043A (es) 2018-07-03 2021-03-25 Univ Illinois Activadores de la respuesta a proteinas desplegadas.
WO2021222738A1 (fr) * 2020-05-01 2021-11-04 The Board Of Trustees Of The University Of Illinois Composés pour cancers positifs au récepteur des oestrogènes
WO2022032146A1 (fr) * 2020-08-07 2022-02-10 Systems Oncology, Llc Procédés d'inhibition de la croissance de cancers era positifs
CN113237860A (zh) * 2021-05-17 2021-08-10 丹望医疗科技(上海)有限公司 检测类器官最大截面积的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES426436A1 (es) * 1974-05-18 1976-07-01 Andreu Sa Dr Procedimiento para la obtencion de derivados de la 3,3-bis (4-hidroxifenil)-2-indolinona.
CA2022356A1 (fr) * 1990-07-31 1992-02-01 David J. Shapiro Methode et matieres pour la production de proteines
CA2555812A1 (fr) * 2004-02-13 2005-09-01 President And Fellows Of Harvard College Oxindoles 3-3-di-substitues utilises en tant qu'inhibiteurs de l'initiation de la traduction
US20070299102A1 (en) * 2004-04-08 2007-12-27 Topo Target A/S Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer
US8383656B2 (en) * 2009-10-09 2013-02-26 The Ohio State University Research Foundation Thiazolidinedione energy restriction-mimetic agents

Also Published As

Publication number Publication date
EP2945646A1 (fr) 2015-11-25
IL240019A0 (en) 2015-09-24
EP2945646A4 (fr) 2016-09-21
AU2014207272A1 (en) 2015-07-30
WO2014113820A1 (fr) 2014-07-24

Similar Documents

Publication Publication Date Title
Xie et al. Atg7 overcomes senescence and promotes growth of Braf V600E-driven melanoma
Britto et al. REDD1 deletion prevents dexamethasone-induced skeletal muscle atrophy
Cao et al. Narciclasine induces autophagy‐dependent apoptosis in triple‐negative breast cancer cells by regulating the AMPK‐ULK1 axis
Bullock FOXO factors and breast cancer: outfoxing endocrine resistance
US20230210852A1 (en) Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
Liu et al. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells
CA2898732A1 (fr) Inhibiteurs d'un recepteur des ƒstrogenes
Hua et al. P7C3‐A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP‐activated protein kinase/CREB regulated transcription coactivator 2 pathway
EP2694073B1 (fr) Combinaisons de inhibiteurs d'akt et mek pour le traitement du cancer
Wang et al. Dopamine suppresses osteoclast differentiation via cAMP/PKA/CREB pathway
KR20170005419A (ko) Pi3k 억제제 피크틸리시브로 pr-양성 내강 a형 유방암을 치료하는 방법
JP2015525063A (ja) 低酸素状態に基づくｈｓｐ９０インヒビターでの治療のための被験者の予備選択
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
WO2017223433A1 (fr) Méthodes et compositions pour le traitement du cancer
KR20220151017A (ko) Er+ 유방암의 라소폭시펜 치료
US10392398B2 (en) Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics
US9802948B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
EP3866787A1 (fr) Compositions et méthodes de suppression et/ou de traitement d'une maladie liée à la croissance et/ou de son état clinique
Schaf et al. Enhanced Sestrin expression through Tanshinone 2A treatment improves PI3K-dependent inhibition of glioma growth
EP2821071A1 (fr) Composés pour le traitement du cancer du sein
JP2019507116A (ja) エストロゲン受容体を活性化する新規化合物ならびにその組成物および使用方法
US20220040134A1 (en) Electrophiles and electrophile pro-drugs as rad51 inhibitors
KR101900278B1 (ko) Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
de Oliveira SIRT1 and mTor Interplay as an Arising Therapeutic Target for Bladder Cancer.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180123